Literature DB >> 10575738

Non-imidazole histamine H3 ligands. Part I. Synthesis of 2-(1-piperazinyl)- and 2-(hexahydro-1H-1,4-diazepin-1-yl)benzothiazole derivatives as H3-antagonists with H1 blocking activities.

K Walczyński1, R Guryn, O P Zuiderveld, H Timmerman.   

Abstract

New 2-(1-Piperazinyl)- and 2-(hexahydro-1H-1,4-diazepin-1-yl)benzothiazoles were prepared and tested as H1- and H3-receptor antagonists. A number of compounds showed weak H1-antagonistic activity, with pA2 values ranging from 5.5 to 6.1. The simple alkyl substituted, 2-[1-(4-methyl and 4-ethyl)piperazinyl] analogues show increasing, moderate H3-antagonistic activity (pA2 = 6.0, and pA2 = 7.0). The compounds with 4-phenylalkyl substitution, for both the piperazinyl and the hexahydro-1H-1,4-diazepin-1-yl homologues series, regardless of the different physicochemical properties of the para substituents at the phenyl ring, showed weak H3-antagonistic activity with pA2 values ranging from 4.4 to 5.6.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10575738     DOI: 10.1016/s0014-827x(99)00081-6

Source DB:  PubMed          Journal:  Farmaco        ISSN: 0014-827X


  3 in total

Review 1.  Multiple Targeting Approaches on Histamine H3 Receptor Antagonists.

Authors:  Mohammad A Khanfar; Anna Affini; Kiril Lutsenko; Katarina Nikolic; Stefania Butini; Holger Stark
Journal:  Front Neurosci       Date:  2016-05-30       Impact factor: 4.677

2.  Acute wake-promoting actions of JNJ-5207852, a novel, diamine-based H3 antagonist.

Authors:  A J Barbier; C Berridge; C Dugovic; A D Laposky; S J Wilson; J Boggs; L Aluisio; B Lord; C Mazur; C M Pudiak; X Langlois; W Xiao; R Apodaca; N I Carruthers; T W Lovenberg
Journal:  Br J Pharmacol       Date:  2004-10-04       Impact factor: 8.739

3.  2-Benzazolyl-4-Piperazin-1-Ylsulfonylbenzenecarbohydroxamic Acids as Novel Selective Histone Deacetylase-6 Inhibitors with Antiproliferative Activity.

Authors:  Lei Wang; Marina Kofler; Gerald Brosch; Jelena Melesina; Wolfgang Sippl; Elisabeth D Martinez; Johnny Easmon
Journal:  PLoS One       Date:  2015-12-23       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.